p63、P-gp、GST-π及Topo-Ⅱ在食管鳞癌组织中的表达-东南大学学报医学版

p63、P-gp、GST-π及Topo-Ⅱ在食管鳞癌组织中的表达

单位：1. 蚌埠医学院, 安徽蚌埠 233000;
2. 蚌埠医学院附属解放军八二医院, 江苏淮安 223001

关键词：食管鳞癌免疫组化 p63 P-糖蛋白谷甘胱肽-S-转移酶π DNA拓扑异构酶

分类号：R735.1

出版年·卷·期（页码）：2016·35·第六期（927-931）

摘要：

目的：观察比较p63、P-糖蛋白（P-gp）、谷甘胱肽-S-转移酶π（GST-π）、DNA拓扑异构酶（Topo-Ⅱ）在食管癌中的表达情况，并探讨其关系和临床意义。方法：采用免疫组化方法对168例食管鳞癌组织中p63、P-gp、GST-π、Topo-Ⅱ蛋白进行检测，分析其与病理特征的关系及协同表达的意义。结果：p63、P-gp、GST-π、Topo-Ⅱ蛋白在食管鳞癌中的阳性表达率分别为81.0%、57.1%、71.4%、78.6%。p63的表达与肿瘤的临床分期、浸润深度、淋巴结转移相关（P<0.05），P-gp和TopoⅡ的表达与淋巴转移有关（P<0.05），GST-π的表达与肿瘤分化程度、淋巴结转移有关（P<0.05）。p63的阳性表达与P-gp、GST-π呈正相关（r=0.193、0.197，P<0.05），P-gp与GST-π表达呈正相关（r=0.224，P<0.05），P-gp与TopoⅡ表达呈负相关（r=-0.218，P<0.05）。结论：p63、P-gp、GST-π及Topo-Ⅱ均与食管癌发生发展有关，对肿瘤化疗方案的选择和预后判断有重要的临床意义。

Objective: To observe and compare the expression of p63, P-glycoprotein(P-gp), glutathione S-transferase π(GST-π)and DNA topoisomerase Ⅱ(Topo-Ⅱ) in esophageal squamous cell carcinoma and discuss the relationships and clincal significance. Methods: The expression of p63, P-gp, GST-π and Topo-Ⅱ in 168 patients with esophageal squamous cell carcinoma were detected by immunohistochemistry, analyzing the relationship of clinicpathological characteristics and the meaning of co-expression. Results: The positive rate of p63, P-gp, GST-π and Topo-Ⅱin esophageal squamous cell carcinoma was 81.0%, 57.1%, 71.4% and 78.6%. p63 positive expression was significantly related to the patients' esophageal clinical stage, invasion degree and lymph node metastasis(P<0.05). The expression of P-gp and Topo-Ⅱ were related to the lymph node metastasis(P<0.05). GST-π was related to the differentiation degree of esophageal cancer tissue and the lymph node metastasis(P<0.05). P-gp and GST-π separately had obviously positive correlation with p63(P<0.05). Positive correlation between the expreesion of P-gp and GST-π was observed(P<0.05), but there was a negative correlation between the expreesion of P-gp and Topo-Ⅱ(P<0.05). Conclusion: p63, P-gp, GST-πand Topo-Ⅱmay probably involve in the tumorigenesis and progress in esophageal squamous cell carcinoma, also might be used in the selection of chemotherapy regimens and in the prognosis of esophageal cancer.

参考文献：

[1] JEMAL A,BRAY F,CENTER M M,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[2] 杜惠惠,任强,刘晓民,等.P-糖蛋白介导的肿瘤多药耐药机制及其逆转策略[J].中华肺部疾病杂志:电子版,2013,6(6):551-553.
[3] GRASSILLI E,NARLOCH R,FEDERZONI E,et al.Inhibition of GSK3 B by-pass drug resistance of p53-null colonc carcinomas by enabling necroptosis in response to chemotherapy[J].Clin Cancer Res,2013,19(14):3820-3831.
[4] 唐郡,阎晓初,彭贵勇,等.食管癌鳞状细胞癌P-gp、GST-π、Topo-Ⅱ的表达及临床意义[J].第三军医大学学报,2007,29(17):1692-1695.
[5] 陈广灿,洪良利,黄杰雄,等.广东潮汕贲门癌组织中GST-π和P-gp的表达及其临床病理意义[J].癌变·畸变·突变,2016,28(1):36-40.
[6] 俞鹏飞,徐琪,应杰儿,等.ToPoⅡ、MRP、GST-π在胃癌组织中的表达及其与预后的关系[J].肿瘤学杂志,2011,17(4):249-252.
[7] YANG A L,KAGHAD M,WANG Y,et al.p63,a p53 homolog at 3q27-29,encodes multiple products with transactivating,death-inducing,and dominant-negative activities[J].Mol Cell,1998,2(3):305-316.
[8] 张超,代红艳,卿晋,等.p63基因的研究进展[J].皮肤病与性病,2012,34(3):142-144.
[9] MELINO G.p63 is a suppressor of tumorigenesis and metastasis interacting with mutant P53[J].Cell Death Differ,2011,18(9):1487-1499.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录